Varaico: Literature-Extracted Genetic Variants

Gene:GLA
Variant:p.F113S
Back to variants list

GLA

NM_000169.3:p.F113S

Associated Papers

Mutation spectrum of α-Galactosidase gene in Japanese patients with Fabry disease.

Kobayashi M et al.

Journal of Human Genetics, 2019

Fabry disease in a Japanese population-molecular and biochemical characteristics.

Sakuraba H et al.

Molecular Genetics and Metabolism Reports, 2018

Challenging popular tools for the annotation of genetic variations with a real case, pathogenic mutations of lysosomal alpha-galactosidase.

Cimmaruta C et al.

Bmc Bioinformatics, 2018

30497360 (PubMed )
Supplement: 12859_2018_2416_MOESM2_ESM.xlsx › ST2

The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.

Benjamin ER et al.

Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017

27657681 (PubMed )
Supplement: gim2016122x1.zip › Supplemental_Appendix_2_12152015.xlsx › Classic

The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations.

Citro V et al.

International Journal of Molecular Sciences, 2016

27916943 (PubMed )
Supplement: ijms-17-02010-s001.zip › ijms-157565-supplementary_file_1_done.xlsx › Tabella_aggiornamento

Genetic Screening of Anderson-Fabry Disease in Probands Referred From Multispecialty Clinics.

Favalli V et al.

Journal of the American College of Cardiology, 2016

Comparative study of structural changes caused by different substitutions at the same residue on α-galactosidase A.

Saito S et al.

Plos One, 2013

A pharmacogenetic approach to identify mutant forms of α-galactosidase A that respond to a pharmacological chaperone for Fabry disease.

Wu X et al.

Human Mutation, 2011

Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study.

Andreotti G et al.

Orphanet Journal of Rare Diseases, 2010

21138548 (PubMed )
Supplement: 1750-1172-5-36-S1.XLS › data

Novel tools for extraction and validation of disease-related mutations applied to Fabry disease.

Kuipers R et al.

Human Mutation, 2010

20629180 (PubMed )
Supplement: supplement_1.pdf

The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines.

Benjamin ER et al.

Journal of Inherited Metabolic Disease, 2009

Fabry disease: twenty novel alpha-galactosidase A mutations and genotype-phenotype correlations in classical and variant phenotypes.

Germain DP et al.

Molecular Medicine (cambridge, Mass.), 2002

Fabry disease: 20 novel GLA mutations in 35 families.

Blaydon D et al.

Human Mutation, 2001

[Molecular genetics of Fabry disease].

Sakuraba H

Seikagaku. the Journal of Japanese Biochemical Society, 1989

Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."